Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool

Sponsor: National Council for Mental Wellbeing


Mortality due to alcohol-related liver disease (ALD) has risen steadily over the past two decades, with a sharp increase during the COVID-19 pandemic. In 2022, 46% of liver disease deaths among people ages 12 and older involved alcohol.

Despite alcohol’s role in liver disease deaths, medication treatments for alcohol use disorder (MAUD) are rarely used in patients with ALD, in part because of stigma, limited data on effectiveness, and concerns about safety and further potential damage to the liver. There is an immense opportunity to increase use of MAUD for patients with or at risk of liver disease to tackle co-occurring health needs and prevent further complications or even death.


Learning Objectives:

-Outline the benefits of MAUD for patients with or at risk of liver disease.

-Describe barriers to MAUD treatment for patients with or at risk of liver disease and explore ways to address these.

-Discuss safe MAUD implementation among patients with liver disease.

The webinar will feature the following speakers: Dr. Lamia Haque, MD, MPH, Hepatologist, Addiction Medicine Specialist, Assistant Professor of Internal Medicine at Yale School of Medicine Dr. Gene Im, MD, FAASLD, Transplant Hepatologist, Associate Professor of Medicine at the Icahn School of Medicine

For more information and to register click here:

Event Details

Date:
June 26, 2024
Time:
1:00 pm - 2:00 pm
Cost:
no costs